The objective response rate in Study 1620 was 29% in patients with laBCC and median DOR was not reached (range: 2.1-21.4+ months)1
The duration of response for this patient was 4.8 months. This patient was no longer in response at the time of data cutoff due to having progressive disease.
This is an example from the 6% of patients who had a CR in Study 1620.1 Individual patient responses may vary.
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc.